Logo image of OGEN

ORAGENICS INC (OGEN) Stock Price, Quote, News and Overview

NYSEARCA:OGEN - NYSE Arca - US6840235005 - Common Stock - Currency: USD

0.197  +0 (+1.49%)

After market: 0.1985 +0 (+0.76%)

OGEN Quote, Performance and Key Statistics

ORAGENICS INC

NYSEARCA:OGEN (4/25/2025, 8:04:00 PM)

After market: 0.1985 +0 (+0.76%)

0.197

+0 (+1.49%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.43
52 Week Low0.16
Market Cap4.23M
Shares21.48M
Float18.62M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13
IPO07-09 2003-07-09


OGEN short term performance overview.The bars show the price performance of OGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

OGEN long term performance overview.The bars show the price performance of OGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of OGEN is 0.197 USD. In the past month the price decreased by -15.81%. In the past year, price decreased by -80.87%.

ORAGENICS INC / OGEN Daily stock chart

OGEN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About OGEN

Company Profile

OGEN logo image Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. The company is headquartered in Sarasota, Florida and currently employs 3 full-time employees. The company went IPO on 2003-07-09. The company is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The company is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Company Info

ORAGENICS INC

1990 Main Street, Suite 750

Sarasota FLORIDA 33634 US

CEO: Alan Joslyn

Employees: 3

Company Website: https://www.oragenics.com/

Investor Relations: http://www.oragenics.com/?q=investors

Phone: 18132867900

ORAGENICS INC / OGEN FAQ

What is the stock price of ORAGENICS INC today?

The current stock price of OGEN is 0.197 USD. The price increased by 1.49% in the last trading session.


What is the ticker symbol for ORAGENICS INC stock?

The exchange symbol of ORAGENICS INC is OGEN and it is listed on the NYSE Arca exchange.


On which exchange is OGEN stock listed?

OGEN stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for ORAGENICS INC stock?

6 analysts have analysed OGEN and the average price target is 1.02 USD. This implies a price increase of 417.77% is expected in the next year compared to the current price of 0.197. Check the ORAGENICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ORAGENICS INC worth?

ORAGENICS INC (OGEN) has a market capitalization of 4.23M USD. This makes OGEN a Nano Cap stock.


How many employees does ORAGENICS INC have?

ORAGENICS INC (OGEN) currently has 3 employees.


What are the support and resistance levels for ORAGENICS INC (OGEN) stock?

ORAGENICS INC (OGEN) has a support level at 0.19 and a resistance level at 0.26. Check the full technical report for a detailed analysis of OGEN support and resistance levels.


Should I buy ORAGENICS INC (OGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ORAGENICS INC (OGEN) stock pay dividends?

OGEN does not pay a dividend.


When does ORAGENICS INC (OGEN) report earnings?

ORAGENICS INC (OGEN) will report earnings on 2025-05-13.


What is the Price/Earnings (PE) ratio of ORAGENICS INC (OGEN)?

ORAGENICS INC (OGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).


What is the Short Interest ratio of ORAGENICS INC (OGEN) stock?

The outstanding short interest for ORAGENICS INC (OGEN) is 0.73% of its float. Check the ownership tab for more information on the OGEN short interest.


OGEN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

OGEN Financial Highlights

Over the last trailing twelve months OGEN reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 78.51% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -717.68%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%94.29%
Sales Q2Q%N/A
EPS 1Y (TTM)78.51%
Revenue 1Y (TTM)-100%

OGEN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 43% to OGEN. The Buy consensus is the average rating of analysts ratings from 6 analysts.


Ownership
Inst Owners2.07%
Ins Owners4.16%
Short Float %0.73%
Short Ratio0.32
Analysts
Analysts43.33
Price Target1.02 (417.77%)
EPS Next Y51.32%
Revenue Next YearN/A